The Phase II Study of Panitumumab in Chemotherapy-Naïve Frail or Elderly Patients with RAS Wild-type Colorectal Cancer: OGSG 1602 Final Results.

Tetsuji TerazawaTakeshi KatoMasahiro GotoKatsuya OhtaHironaga SatakeShingo NouraYoshinori KagawaHisato KawakamiHiroko HasegawaKazuhiro YanagiharaTatsushi ShingaiKen NakataMasahito KotakaMasayuki HirakiKen KonishiShiro NakaeDaisuke SakaiYukinori KurokawaToshio ShimokawaToshimasa TsujinakaTaroh Satoh

Published in: The oncologist (2022)

Panitumumab showed favorable OS in frail or elderly patients with RAS wild-type CRC and no prior exposure to chemotherapy. Panitumumab may be optimal for patients with LSTs (UMIN Clinical Trials Registry Number UMIN000024528).

Keyphrases

wild type
phase ii study
community dwelling
locally advanced
clinical trial
rectal cancer
open label
middle aged
squamous cell carcinoma
radiation therapy
chemotherapy induced